About 1 in every 526 people in the U.S. will be diagnosed with chronic myeloid leukemia (CML) this year, but most of these people will achieve their normal life expectancy thanks to tyrosine kinase ...

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the ASRS meeting, ...

A real-world study demonstrated better survival outcomes when an immunotherapy is combined with a tyrosine kinase inhibitor rather than another immunotherapy therapy for intermediate-risk renal cell ...

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to ...

Treatment with a vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFR–TKI) after previous treatment with checkpoint-inhibitor therapy alone or in combination with a VEGFR–TKI ...

BEDFORD, Mass., Feb. 11, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ...

Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. Many patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SALT LAKE CITY — In this Healio Video Perspective from ...